Hybrid Telecoaching for Corporate Speech Training and Potential Applications to Clinical Practice

2019 ◽  
Vol 4 (2) ◽  
pp. 322-324
Author(s):  
Thomas F. Burke
Keyword(s):  
Clinical Practice ◽  
Engineering Teams ◽  
Corporate Strategies ◽  
Corporate Speech ◽  
Phone Calls ◽  
Future Clinical Practice ◽  
Fortune 100 ◽  
Potential Applications ◽  
Language Pathology ◽  
Development Engineering

Purpose The purpose of this article was to describe a model for “hybrid speech telecoaching” developed for a Fortune 100 organization and offer a “thought starter” on how clinicians might think of applying these corporate strategies within future clinical practice. Conclusion The author contends in this article that corporate telecommunications and best practices gleaned from software development engineering teams can lend credibility to e-mail, messaging apps, phone calls, or other emerging technology as viable means of hybrid telepractice delivery models and offer ideas about the future of more scalable speech-language pathology services.

Genetic and epigenetic variation in vulvar cancer: Current research and future clinical practice

2014 ◽  
Vol 54 (5) ◽  
pp. 406-411 ◽  
Author(s):  
Rebekah E. McWhirter ◽  
James R. Marthick ◽  
Jacqueline A. Boyle ◽  
Joanne L. Dickinson
Keyword(s):  
Clinical Practice ◽  
Vulvar Cancer ◽  
Epigenetic Variation ◽  
Future Clinical Practice

scholarly journals PHYSICAL ACTIVITY OF PHYSIOTHERAPY STUDENTS AND THE ROLE OF DEVICE-BASED MONITORING IN THEIR FUTURE CLINICAL PRACTICE: A COHORT STUDY

2020 ◽  
Vol 14 (2) ◽  
pp. 107-117
Author(s):  
Tamara Michalčíková ◽  
Michal Vorlíček ◽  
Jana Pechová ◽  
Lukáš Jakubec ◽  
Karel Frömel ◽  
...  
Keyword(s):  
Physical Activity ◽  
Cohort Study ◽  
Clinical Practice ◽  
Future Clinical Practice ◽  
Physiotherapy Students

Could advanced drug delivery systems be the future in cardiovascular revascularization medicine?

Vascular ◽  
2016 ◽  
Vol 25 (4) ◽  
pp. 447-448 ◽  
Author(s):  
Marco Zuin ◽  
Gianluca Rigatelli ◽  
Giuseppe Faggian ◽  
Roberto L’Erario ◽  
Mauro Chinaglia ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Pulmonary Embolism ◽  
Clinical Practice ◽  
Percutaneous Transluminal Coronary Angioplasty ◽  
Massive Pulmonary Embolism ◽  
Bleeding Events ◽  
Systemic Thrombolysis ◽  
Future Clinical Practice ◽  
Transluminal Coronary Angioplasty

Acute myocardial infarction, stroke and pulmonary embolism required a prompt revascularization to restore the normal blood flow as soon as possible. Fibrinolytic treatment has gradually become both dated and underused in the treatment of acute myocardial infarction, after the wide diffusion of cathlab and percutaneous transluminal coronary angioplasty. Conversely, the use of systemic thrombolysis remained a benchmark in the treatment of both ischemic stroke and massive pulmonary embolism. In daily clinical practice, the use of thrombolytic agents is often limited by absolute and/or relative contraindications and possible adverse events after the drug administration, as intracranial and/or extracranial bleeding events. To minimize these problems, during the last years, the introduction of nanotechnology in the field of cardiovascular revascularization medicine has created several fascinating results. In the present article, we describe these recent findings and their possible implications in future clinical practice.

Sign in / Sign up

Export Citation Format

Share Document